Tuesday, October 24, 2006
Article in today's New York Times -- New Safety Data on Stents Fails to Settle Debate, by Barnaby J. Feder:
New safety data presented here today at a conference for doctors who implant
cardiovascular stents did little to settle the debate over whether the devices are
being used too often and in the wrong patients.
By the end of the day, the consensus of many of the experts appeared to be that
the long-terms risks of deadly clotting from drug-coated heart stents had been
exaggerated in recent weeks.
And yet, the experts on a number of panels concluded that the emerging data
required a more cautious approach to stenting. For at least the two best selling
drug-coated brands, Boston Scientific’s Taxus and Johnson & Johnson’s Cypher,
many experts agreed, there appears to be a long-term clotting risk compared
with the use of older bare metal stents.